A Long-Term Follow-Up Study of Participants Exposed to REACT
← catalyst calendarNCT05918523 · readout ≤ 530 d
Sponsored by Prokidney (industry) · PROK — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
80estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-11 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetic Kidney Disease
- Chronic Kidney Diseases
Intervention
- Biological: Renal Autologous Cell Therapy (REACT)
Primary outcome
what the primary-completion date above is the date OFPrimary Endpoint: Long-term safety of REACT
measured 60 months from completion of parent protocol EOS Visit
Permalink · PROK's whole pipeline · Catalyst calendar · Every registered study · What changed